Ep 24: Insitro CEO Daphne Koller on Using ML to Change Drug Discovery

episode

Vital Signs with Jacob Effron and Nikhil Krishnan not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded13 Jun 2023

Publisherfeeds.simplecast.com ↗

Handlerec:14380999

Show notes

Jacob sits down with Insitro CEO Daphne Koller to discuss founding Coursera, where and how ML can drive the most impact in drug development, and if foundation models can transform core drug discovery work and edtech. 00:00 intro00:59 Daphne’s journey09:02 AI and biology discovery10:42 insitro vs. traditional pharma19:47 phenotyping patients25:44 early mistakes29:34 the future of data35:16 partnering with larger pharma companies38:00 impact of LLMs on biopharma43:47 over-hyped/under-hyped

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in